NuVasive (NASDAQ:NUVA) will be posting its quarterly earnings results after the market closes on Tuesday, October 30th. Analysts expect NuVasive to post earnings of $0.63 per share for the quarter. NuVasive has set its FY18 guidance at $2.37-2.40 EPS.
NuVasive (NASDAQ:NUVA) last announced its quarterly earnings results on Tuesday, July 31st. The medical device company reported $0.58 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.58. NuVasive had a net margin of 3.96% and a return on equity of 13.70%. The firm had revenue of $281.56 million during the quarter, compared to analysts’ expectations of $276.05 million. On average, analysts expect NuVasive to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Shares of NASDAQ NUVA opened at $62.12 on Friday. NuVasive has a 52-week low of $44.62 and a 52-week high of $72.41. The company has a market capitalization of $3.24 billion, a price-to-earnings ratio of 32.52, a price-to-earnings-growth ratio of 1.73 and a beta of 0.69.
NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.
See Also: Stock Symbol
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.